dihydropyrimidine

5,6-Dihydrouracil (5,6-Dihydrouracil) is an intermediate breakdown product of uracil.

TAS-114 is an orally active dual inhibitor of dUTPase and dihydropyrimidine dehydrogenase (DPD). TAS-114 targets the intercellular metabolism of 5-FU to enhance antitumor activity and modulates catabolic pathways to improve the systemic availability of 5-FU.

Eniluracil (GW776C85) is an orally activedihydropyrimidine dehydrogenase (DPD) inhibitor,increases the oral bioavailability of 5-FU to 100%, facilitating uniform absorption and predictable toxicity.

Ethyl 2-(methylthio)-6-oxo-1,6-dihydropyrimidine-5-carboxylate is a useful organic compound for research related to life sciences. The catalog number is T64927 and the CAS number is 53554-29-3.

6-Phenyldihydropyrimidine-2,4(1h,3h)-dione targets the polypyrimidine tract-binding protein 1 isoform a (human)

DCH36_06 ((5E)-1-(3-chloro-4-methylphenyl)-5-[(2E)-3-(furan-2-yl)prop-2-en-1-ylidene]-2-thioxodihydropyrimidine-4,6(1H,5H)-dione)  as a bona fide is a potent p300/CBP inhibitor

5,6-dihydro-5-Fluorouracil (5-FUH2) is an inactive metabolite of 5-FU and can be used for the study of organismal metabolism.

Gimeracil (Gimestat) is a competitive, reversible inhibitor of dihydropyrimidine dehydrogenase.

Doxifluridine (AMC 0101) is a fluoropyrimidine derivative and oral prodrug of the antineoplastic agent 5-fluorouracil (5-FU) with antitumor activity. Doxifluridine, designed to circumvent the rapid degradation of 5-FU by dihydropyrimidine dehydrogenase in the gut wall, is converted into 5-FU in the presence of pyrimidine nucleoside phosphorylase. 5-FU interferes with DNA synthesis and subsequent cell division by reducing normal thymidine production and interferes with RNA transcription by competing with uridine triphosphate for incorporation into the RNA strand.

EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.

tDHU, acid is a dihydropyrimidine cereblon ligand consisting of an E3 ligase ligand and a benzoic acid linker. It serves as an E3 ubiquitin ligase ligand-linker conjugate in the development of PROTACs.

EGFR/HER2-IN-15 is a dihydropyrimidine and an effective inhibitor of EGFR/HER2. It significantly suppresses EGFRwt activity with an IC50 of 37.21 nM and exhibits anticancer properties.

(E)-5-(2-Bromovinyl)uracil (BVU) is a pyrimidine base and an inactive metabolite of the antiviral agents sorivudine and (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), which can be regenerated to BVDU in vivo. BVU irreversibly inactivates dihydropyrimidine dehydrogenase (DPD) in an NADPH-dependent manner, enhancing the efficacy of the chemotherapeutic agent and DPD substrate 5-fluorouracil in a P388 murine leukemia model when administered at a dose of 200 μmol/kg, thereby increasing survival time.

SQ 32547 is a dihydropyrimidine calcium channel antagonist

Dihydrouracil-d4 is the deuterated form of Dihydrouracil. Dihydrouracil itself is a metabolite of uracil and serves as a marker for identifying deficiencies in dihydropyrimidine dehydrogenase (DPD).

Gimeracil (Standard) is a reference standard for research and analysis in studies involving Gimeracil. Gimeracil (Gimestat) is a competitive, reversible inhibitor of dihydropyrimidine dehydrogenase.

Doxifluridine (Standard) is a reference standard for research and analysis in studies involving Doxifluridine. Doxifluridine (AMC 0101) is a fluoropyrimidine derivative and oral prodrug of the antineoplastic agent 5-fluorouracil (5-FU) with antitumor activity. Doxifluridine, designed to circumvent the rapid degradation of 5-FU by dihydropyrimidine dehydrogenase in the gut wall, is converted into 5-FU in the presence of pyrimidine nucleoside phosphorylase. 5-FU interferes with DNA synthesis and subsequent cell division by reducing normal thymidine production and interferes with RNA transcription by competing with uridine triphosphate for incorporation into the RNA strand.